Marco Gobbi

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

Philipp le Coutre, Oliver G. Ottmann, Francis J. Giles et al. · Blood · 2007 · 291 citations · Full text

Medicine, Oncology, Pharmacology +4

Unmanipulated Haploidentical Transplants Compared with Other Alternative Donors and Matched Sibling Grafts

Anna Maria Raiola, Alida Dominietto, Carmen Di Grazia et al. · Biology of Blood and Marrow Transplantation · 2014 · 279 citations · Full text

Medicine, Hematology, Immunology +15

Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study

Francesco Frassoni, Francesca Gualandi, Marina Podestà et al. · The Lancet Oncology · 2008 · 260 citations

Medicine, Hematology, Oncology +17

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani et al. · Leukemia · 2018 · 247 citations · Full text

Medicine, Oncology, Pharmacology +16

International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Gail J. Roboz, Todd Rosenblat, Martha Arellano et al. · Journal of Clinical Oncology · 2014 · 202 citations · Full text

Medicine, Oncology, Pharmacotherapy +13